PhagoMed Biopharma is a biotechnology company developing phage therapies to replace ineffective antibiotics that is headquartered in Vienna, Austria and was founded in 2017 by Alexander Belcredi and Burkhard Wippermann.
Virtual tour of PhagoMed Biopharma.
PM398 is a phage therapy designed to destroy multi-drug resistant methicillin-resistant Staphylococcus aureus (MRSA).
PhagoMed PM398 in action.
On August 28, 2018 PhagoMed Biopharma completed a seed funding round with €4M in funding from from undisclosed investors.
Timeline
Funding Rounds
Patents
Further Resources
PhagoMed - Virtual Tour (aws Phoenix video in English)
February 13, 2019
PhagoMed Biopharma uses technology to find alternative to antibiotics
January 8, 2019
References
Organization
CompanyCompany attributes
Therapeutics
Phage therapy
Microbiome
Technology
Biology
Biotechnology
Drug discovery
Vienna
Austria
B2B
BioNTech
Austria Wirtschaftsservice Gesellschaft
Seed roundCategories
Related Topics
Contributors
- 1
Dawson Sewell
Writing about startups. - 2
Katrina-Kay Pettitt
Data Duchess @ Golden - 3
Elena Ruban
Freelancer now. Graduated from Financial University - 4
Meredith Hanel
Medical Genetics PhD, following life science applications that improve the health of humans and our planet. - 5
Wyckliffe Otieno
Dedicated information technology enthusiast. - 6
Lax Mariappan
Technopreneur, Open source enthusiast, author, speaker. Co-founder of Eternus Global. Crafting applications for the medical industry. - 7
Vlad Botushninu
I am a beginner programmer, I study IT sphere and cryptocurrencies - 8
Ирина Носкова
Programmer - 9
Marie Gabrielle Laguna- Bedia
Co-founder and Managing Partner of Eternus Global. Physician of internal medicine, app developer and entrepreneur - 10
Neelam Jhaveri
Techno Geek + Gamer + Fashionista + Sense of Humor = It's ME